Mechanistic Insights into Org 43553-Induced Energy Expenditure In Vitro
JSHS · 2025
Overview
The obesity epidemic, a leading driver of chronic diseases such as cardiovascular disease and type II diabetes, remains inadequately addressed by current pharmacological treatments. GLP-1 agonists, while effective in appetite suppression, frequently cause adverse side effects, including significant lean mass loss, underscoring the need for innovative therapies. Org 43553, a low - molecular-weight agonist of the luteinizing hormone receptor (LHCGR), presents a promising alternative by selectively preventing fa t gain in vivo. This study investigates the mechanisms by which Org 43553 enhances energy expenditure in vitro, utilizing 3T3-L1 adipocytes as a model system. Our results reveal that Org 43553 significantly increases intracellular oxygen consumption rate (OCR) in a dose -dependent manner, independently of UCP1 activation, suggesting a unique pharmacologic pathway f or fat loss induction. Furthermore, Org 43553 triggers phospholipase C (PLC) activity but not cAMP production, activating a calcium - and extracellular signal-regulated kinase (ERK 1/2) -dependent signaling cascade. RNA sequencing identified ATF3 as a key upregulated transcription factor, along with its downstream targets, suggesting its potential involvement in enhancing mitochondrial activity and en ergy expenditure. The role of ATF3 was further validated with siAtf3 knockdown experiments, confirming its function as a primary driver of Org 43553 -induced changes in mitochondrial respiration. Ultimately, our findings uncover a previously uncharacterized non-canonical mechanism by which Org 43553 stimulates energy expenditure in adipose tissue, underscoring its potential as a next -generation obesity therapy and establishing a foundation for future research into targeted metabolic disease treatments.
Competition history
- JSHS 2025
Resources
Related projects
ISEF · 2018
The Role of Sarcolipin Protein on Energy Expenditure and Obesity Prevention
ISEF · 2017
Designing and Testing a Novel Drug Targeting the Distinct Metabolic Roles of the Isoforms of PPARGamma
ISEF · 2024
The Impact of Adenylate Cyclase 3 Loss in SF1 Neurons on Obesity
JSHS · 2024
Turning Fat to Muscle by Activating Muscle-Specific Genes
ISEF · 2016
The Molecular Basis of the Transdifferentiation of Embryonic Chick Limb Chondrogenic Precursors into a Beige Fate
JSHS · 2025
Heartland GDF15 and FGF21 Improve Glucose Metabolism in Mice Lacking OPA1 in Brown Adipose Tissue
ISEF · 2020
Human Genetic Variant OtpQ153R/+ Causes Excessive Weight Gain and Glucose Intolerance in Mice
ISEF · 2026
Pharmacoperone-Mediated Rescue of Melanocortin-4 Receptor: Evaluating SM-001 in Restoring Intracellular cAMP Signaling
Closest projects by meaning, across every fair and year in the corpus.